BindingDB logo
myBDB logout

35 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27133596 20 State of affairs: Design and structure-activity relationships of reversible P2Y12 receptor antagonists.EBI Galecto Biotech
25638496 2 GPCR crystal structures: Medicinal chemistry in the pocket.EBI Friedrich Alexander University
25113932 51 Optimization of 2-phenyl-pyrimidine-4-carboxamides towards potent, orally bioavailable and selective P2Y(12) antagonists for inhibition of platelet aggregation.EBI Actelion Pharmaceuticals Ltd
25075638 210 N-[6-(4-butanoyl-5-methyl-1H-pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1H-indole-3-carboxamide (SAR216471), a novel intravenous and oral, reversible, and directly acting P2Y12 antagonist.EBI Sanofi R&D
24931384 66 Discovery of 4-aryl-7-hydroxyindoline-based P2Y1 antagonists as novel antiplatelet agents.EBI Bristol-Myers Squibb Research
24835983 38 Optimization of ketone-based P2Y(12) receptor antagonists as antithrombotic agents: pharmacodynamics and receptor kinetics considerations.EBI AstraZeneca
24513044 19 Identification of 1-{2-[4-chloro-1'-(2,2-dimethylpropyl)-7-hydroxy-1,2-dihydrospiro[indole-3,4'-piperidine]-1-yl]phenyl}-3-{5-chloro-[1,3]thiazolo[5,4-b]pyridin-2-yl}urea, a potent, efficacious and orally bioavailable P2Y(1) antagonist as an antiplatelet agent.EBI Bristol-Myers Squibb
24164581 82 Conformationally constrained ortho-anilino diaryl ureas: discovery of 1-(2-(1'-neopentylspiro[indoline-3,4'-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a potent, selective, and bioavailable P2Y1 antagonist.EBI Bristol-Myers Squibb Company
24332627 26 Synthesis and biological evaluation of cyclopentyl-triazolol-pyrimidine (CPTP) based P2Y12 antagonists.EBI Shanghai Hengrui Pharmaceutical Co. Ltd
23899349 69 Lead optimization of ethyl 6-aminonicotinate acyl sulfonamides as antagonists of the P2Y12 receptor. separation of the antithrombotic effect and bleeding for candidate drug AZD1283.EBI AstraZeneca
23747805 124 Synthesis, structure-property relationships and pharmacokinetic evaluation of ethyl 6-aminonicotinate sulfonylureas as antagonists of the P2Y12 receptor.EBI AstraZeneca
23602442 28 Discovery of diarylurea P2Y(1) antagonists with improved aqueous solubility.EBI Bristol-Myers Squibb
23368907 62 Discovery of 2-(phenoxypyridine)-3-phenylureas as small molecule P2Y1 antagonists.EBI Bristol-Myers Squibb Research and Development
17827008 3 From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis.EBI AstraZeneca
22984835 66 Identification of high-affinity P2Y12 antagonists based on a phenylpyrazole glutamic acid piperazine backbone.EBI Sanofi-Aventis Deutschland GmbH
21207957 163 Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor.EBI University of Bonn
19463000 50 High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors.EBI University of Bonn
18276138 22 Adenosine analogues as inhibitors of P2Y12 receptor mediated platelet aggregation.EBI Inspire Pharmaceuticals, Inc.
18232657 67 Lipophilic modifications to dinucleoside polyphosphates and nucleotides that confer antagonist properties at the platelet P2Y12 receptor.EBI Inspire Pharmaceuticals, Inc.
12213051 207 Purine and pyrimidine (P2) receptors as drug targets.EBI National Institute of Diabetes
21507636 140 A novel series of piperazinyl-pyridine ureas as antagonists of the purinergic P2Y12 receptor.EBI AstraZeneca R&D
20394377 12 Frontal affinity chromatography-mass spectrometry useful for characterization of new ligands for GPR17 receptor.EBI University of Pavia
20141147 257 Piperazinyl glutamate pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.EBI Pfizer Global Research& Development
20097563 88 Part II: piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.EBI Pfizer Global Research& Development
19796941 210 Piperazinyl-glutamate-pyrimidines as potent P2Y12 antagonists for inhibition of platelet aggregation.EBI Pfizer Global Research and Development
19748783 52 Thienopyrimidine-based P2Y12 platelet aggregation inhibitors.EBI Pfizer Global Research and Development
19604694 147 Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation.EBI Pfizer Global Research& Development
19739647 52 5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).EBI Amira Pharmaceuticals
19464902 1 6-Amino-2-mercapto-3H-pyrimidin-4-one derivatives as new candidates for the antagonism at the P2Y12 receptors.EBI Universit£ di Ferrara
16213725 1 Synthesis and preliminary evaluation of [3H]PSB-0413, a selective antagonist radioligand for platelet P2Y12 receptors.EBI University of Bonn
12729666 2 A new sterol sulfate, Sch 572423, from a marine sponge, Topsentia sp.EBI Schering-Plough Research Institute
11459636 16 Novel tricyclic benzothiazolo[2,3-c]thiadiazine antagonists of the platelet ADP receptor (P2Y(12)).EBI COR Therapeutics, Inc.
8336341 42 Synthesis and biological evaluation of antiplatelet 2-aminochromones.EBI Upjohn Laboratories
1321910 160 Inhibitors of blood platelet cAMP phosphodiesterase. 2. Structure-activity relationships associated with 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-ones substituted with functionalized side chains.EBI Bristol-Myers Squibb Pharmaceutical Research Institute